Art. -Nr.: HY-15473

MLN120B

Name: MLN120B
Brand: MedChemExpress
SKU: HY-15473
Price: 132.00 USD
Availability: InStock
Rating: 5 (28 reviews)

(Synonyms: ML120B)

28 Cited Publications

Kundenbewertung

Based on 28 publication(s) in Google Scholar

MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC₅₀ of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.76%
CAS. Nr.: 783348-36-7
Formel: C₁₉H₁₅ClN₄O₂
Molecular Weight:366.80

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

MLN120B Chemical Structure

CAS. Nr.: 783348-36-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (28)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[4]

IKKβ

60 nM (IC₅₀)

Alle IKK Isoform-spezifische Produkte anzeigen :

In Vitro

MLB120B (0-20 μM; 90 minutes) inhibits phosphorylation and degradation of IκB in RPMI 8226 and INA6 cells; however, no significant inhibition is observed in MM.1S cells^[1].
MLB120B (1.25-20 μM; 90 minutes) completely abrogates TNF-a-induced phosphorylation and degradation of IκB in a dosedependent fashion. Phosphorylation of p65 NF-κB induced by TNF-a is also blocked by MLN120B^[1].
MLN120B inhibits proliferation of multiple myeloma cell lines. MM.1S, MM.1R, RPMI 8226, RPMI-LR5, RPMI-Dox40, U266, and INA6 cells. Five percent to fifty percent and 18% to 70% inhibition in proliferation is observed at doses >20 uM and [³H]thymidine uptake, respectively[1].
MLN120B (1.25-40 μM; 72 hours) almost completely blocks stimulation of MM.1S, U266, and INA6 cell growth, as well as IL-6 secretion from BMSCs, induced by multiple myeloma cell adherence to BMSCs[1].
MLN120B shows an inhibitory effect on LPS induced NF-κB activation in RAW267.4 cells. The IC₅₀ values of MLN120B is 1.4 μM, 14.8 μM or 27.3 μM for NF-κB2-luc2, IL8-luc2 or TNF-AIP3-luc2 reporter transfected cells, respectively[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MM.1S cells
Concentration:

1.25-20 μM
Incubation Time:

90 minutes
Result:

Inhibited p- IκB and p-P65 expression in a dose-dependent manner.

Cell Viability Assay^[1]

Cell Line:

Multiple myeloma cell lines: MM.1S, MM.1R, RPMI 8226, RPMI-LR5, RPMI-Dox40, U266, and INA6 cells
Concentration:

1.25 μM-20 μM
Incubation Time:

72 hours
Result:

Inhibits proliferation of multiple myeloma cell lines.

In Vivo

MLN120B (oral administration; 50 mg/kg; twice daily; 3 weeks) induces a reduction of shuIL-6R, marker of tumor growth, marker of tumor growth. It also leads to a rend toward prolonged survival in animals treated versus control^[1].
MLN120B (oral administration; 1-30 mg/kg; twice daily; 3 weeks) inhibits paw swelling in a dose-dependent manner and offers significant protection against arthritis-induced weight loss as well as cartilage and bone erosion. NF-κB activity in arthritic joints is also reduced after MLN120B administration^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Two-month-old female Lewis rats^[2]
Dosage:

30 mg/kg, 10 mg/kg, 3 mg/kg, or 1 mg/kg
Administration:

Oral administration; twice daily; 3 weeks
Result:

Protected against bone and cartilage destruction in a rat model.

Animal Model:

SCID mice implanted with human fetal bone chips and then INA6 cells are directly injected into mice^[1]
Dosage:

50 mg/kg
Administration:

Oral administration; twice daily; 3 weeks
Result:

Inhibited human multiple myeloma cell growth in vivo.

Chemical Information

CAS. Nr. 783348-36-7
Appearance Solid
Molecular Weight 366.80
Formel C₁₉H₁₅ClN₄O₂
Color Off-white to light yellow
SMILES

O=C(C1=CC=CN=C1C)NC2=C(OC)C(Cl)=CC3=C2NC4=C3C=CN=C4
Synonyms

ML120B
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (28)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. [Abstract]

2020 Oct 9;5(1):235. PMID: 33037188
Cancer Cell

Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. [Abstract]

2024 Feb 12;42(2):238-252.e9. PMID: 38215749
Nature

Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. [Abstract]

2022 Oct;610(7931):366-372. PMID: 36198801
Blood

2023 Nov 2.
Blood

ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans. [Abstract]

2015 Nov 12;126(20):2291-301. PMID: 26400962
Blood

NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity. [Abstract]

2015 Sep 10;126(11):1324-35. PMID: 26153519
Sci Transl Med

A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. [Abstract]

2021 Jan 27;13(578):eaba7308. PMID: 33504651
Theranostics

Tumor-neuroglia interaction promotes pancreatic cancer metastasis. [Abstract]

2020 Apr 6;10(11):5029-5047. PMID: 32308766
Cell Death Dis

Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity. [Abstract]

2016 Dec 1;7(12):e2505. PMID: 27906189
Acta Pharmacol Sin

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. [Abstract]

2021 May;42(5):814-823. PMID: 32855532
Aging Cell

NF-κB/IKK activation by small extracellular vesicles within the SASP. [Abstract]

2021 Jul;20(7):e13426. PMID: 34187082
Cell Rep

SFTSV Infection Induces BAK/BAX-Dependent Mitochondrial DNA Release to Trigger NLRP3 Inflammasome Activation. [Abstract]

2020 Mar 31;30(13):4370-4385.e7. PMID: 32234474
Cell Prolif

Intercellular mitochondrial transfer alleviates pyroptosis in dental pulp damage. [Abstract]

2023 Sep;56(9):e13442. PMID: 37086012
J Invest Dermatol

The Unknown Aspect of BAFF: Inducing IL-35 Production by a CD5+CD1dhiFcγRIIbhi Regulatory B-Cell Subset in Lupus. [Abstract]

2017 Dec;137(12):2532-2543. PMID: 28844943

MLN120B purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2017 Dec;137(12):2532-2543. [Abstract]

MZ B cells are pre-treated with different concentrations of MLN120B, which selectively inhibit NF-κB1 pathway, the expression of p35 and Ebi3 significantly reduced.
Biochem Pharmacol

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. [Abstract]

2018 Jun:152:45-59. PMID: 29551587

MLN120B purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Jun:152:45-59. [Abstract]

Effects of NF-κB inhibitor (10 μM MLN120B) is measured on p62 protein in LPS-induced RAW264.7 cells.
Int Immunopharmacol

Inflammatory factor-mediated miR-155/SOCS1 signaling axis leads to Treg impairment in systemic lupus erythematosus. [Abstract]

2024 Nov 15:141:113013. PMID: 39213866
Sci Rep

A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation. [Abstract]

2021 Jul 28;11(1):15319. PMID: 34321581
Int J Cancer

Synergy of interleukin 10 and toll-like receptor 9 signalling in B cell proliferation: Implications for lymphoma pathogenesis. [Abstract]

2017 Mar 1;140(5):1147-1158. PMID: 27668411
J Biol Chem

Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. [Abstract]

2015 Apr 24;290(17):11061-74. PMID: 25762719
Viruses

Activation of the STAT3 Signaling Pathway by the RNA-Dependent RNA Polymerase Protein of Arenavirus. [Abstract]

2021 May 25;13(6):976. PMID: 34070281
Cytokine

The LA-NF-κB-ILC2 axis exacerbates intestinal milk protein allergy in mice by promoting ILC2 activation. [Abstract]

2026 May:201:157135. PMID: 41780286
Exp Ther Med

Proteomic and microRNA-omic profiles and potential mechanisms of dysfunction in pancreatic islet cells primed by inflammation. [Abstract]

2021 Feb;21(2):122. PMID: 33335585
bioRxiv

2025 February 22.
University of Strathclyd

2024
bioRxiv

2024 Mar 28.
bioRxiv

2023 Mar 23.
Patent

US20220025002A1.
SSRN

2022 Jan 26.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 31 mg/mL (84.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7263 mL

13.6314 mL

27.2628 mL

5 mM

0.5453 mL

2.7263 mL

5.4526 mL

10 mM

0.2726 mL

1.3631 mL

2.7263 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (5.67 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hideshima T, et all. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 1;12(19):5887-94. [Content Brief]

[2]. Schopf L, et al. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54(10):3163-73. [Content Brief]

[3]. Ansaldi D, et al. Imaging pulmonary NF-kappaB activation and therapeutic effects of MLN120B and TDZD-8. PLoS One. 2011;6(9):e25093. [Content Brief]

[4]. Nagashima K, et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood. 2006 Jun 1;107(11):4266-73. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7263 mL	13.6314 mL	27.2628 mL	68.1570 mL
	5 mM	0.5453 mL	2.7263 mL	5.4526 mL	13.6314 mL
	10 mM	0.2726 mL	1.3631 mL	2.7263 mL	6.8157 mL
	15 mM	0.1818 mL	0.9088 mL	1.8175 mL	4.5438 mL
	20 mM	0.1363 mL	0.6816 mL	1.3631 mL	3.4079 mL
	25 mM	0.1091 mL	0.5453 mL	1.0905 mL	2.7263 mL
	30 mM	0.0909 mL	0.4544 mL	0.9088 mL	2.2719 mL
	40 mM	0.0682 mL	0.3408 mL	0.6816 mL	1.7039 mL
	50 mM	0.0545 mL	0.2726 mL	0.5453 mL	1.3631 mL
	60 mM	0.0454 mL	0.2272 mL	0.4544 mL	1.1360 mL
	80 mM	0.0341 mL	0.1704 mL	0.3408 mL	0.8520 mL

Bioz

Keywords

MLN120B

28 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MLN120B

BMS-345541

IMD-0354

ACHP Hydrochloride

BAY 11-7082

BI605906

IKK 16

TPCA-1

BAY 11-7085

Bay 65-1942 hydrochloride

Amlexanox

JSH-23

Rapamycin

Publications Citing Use of MedChemExpress (MCE) MLN120B

Alle IKK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (28)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

MLN120B

BMS-345541

IMD-0354

ACHP Hydrochloride

BAY 11-7082

BI605906

IKK 16

TPCA-1

BAY 11-7085

Bay 65-1942 hydrochloride

Amlexanox

JSH-23

Rapamycin

Publications Citing Use of MedChemExpress (MCE) MLN120B

Alle IKK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (28)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MLN120B Related Classifications

HY-15473 Related Classifications

Bioz